Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Britain Courts Anthropic Amid US Defense Department Dispute 
PITTSBURGH, Sept. 20, 2017 -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that President & CEO Kenneth I. Moch will present at the Ladenburg Thalmann 2017 Healthcare Conference at 9:00 a.m. on September 26, 2017 at the Sofitel New York Hotel. Mr. Moch’s presentation will include a corporate update as well as a discussion of CT1812, the company’s small molecule drug candidate for the treatment of mild-to-moderate Alzheimer’s disease.
About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class, orally available small molecule. This highly brain penetrant compound targets the sigma-2 receptor complex, displacing toxic beta amyloid oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. In Cognition’s recently completed Study COG0102, patients with mild-to-moderate Alzheimer’s disease were randomized to one of three doses of CT1812 or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Detailed results of this Phase 1b/2 study are anticipated to be announced at the CTAD (Clinical Trials on Alzheimer's disease) meeting in Boston in November 2017. Additional information about Cognition may be found online at http://www.cogrx.com.
Cognition Therapeutics, Inc. [email protected] Aline Sherwood Scienta Communications [email protected]
